Company intelligence / Profile preview

IntelliGenome

Houston, Texas, United States

Ownership: Private
Employees: ~1
Development stage: Other

Overview

IntelliGenome's CRISPR-TB Blood Test received FDA Breakthrough Device Designation (2025) for sensitive, non-sputum detection of active TB from blood; enables improved diagnosis for vulnerable and hard-to-test populations. Clinical validation underway; global multicenter studies planned for 2025.

Therapeutic areas: Infectious Diseases
Modalities: CRISPR-based diagnostic platformDevice
Industry: Molecular Diagnostics

Partnerships

Tulane University (research collaboration for CRISPR technology)

Beyond the preview

Go deeper on IntelliGenome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IntelliGenome.

Explore the full profile